N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

Conditions: Glioblastoma Interventions: Drug: Bevacizumab; Drug: PD-L1 t-haNK; Drug: N-803 Sponsors: ImmunityBio, Inc. Not yet recruiting

Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials